Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Company Overview

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics. This LNP platform underpins the company’s RNAi assets and has been the foundation for collaborations with other biopharmaceutical organizations seeking efficient delivery systems for mRNA and RNA-based medicines. Arbutus’ focus on innovative delivery solutions complements its antiviral drug discovery capabilities, positioning it at the forefront of HBV research and development.

Founded through the merger of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus maintains dual operations in Warminster, Pennsylvania, and Vancouver, British Columbia. The company’s leadership team combines experience in virology, lipid chemistry and pharmaceutical development, supporting strategic alliances with academic institutions and contract research organizations worldwide. Arbutus continues to engage with global regulatory authorities to advance its clinical trials and seeks partnerships to broaden the reach of its potential HBV therapies.

Key Stats

• Today's Range: $4.51 to $4.65
• 50-Day Range: $4.12 to $5.22
• 52-Week Range: $3.31 to $5.38
• Volume: 1.39 million shs
• Average Volume: 1.38 million shs
• Market Capitalization: $904.73 million
• P/E Ratio: 5.80
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Arbutus Biopharma Stock Analysis - MarketRank™

Arbutus Biopharma scored higher than 26% of companies evaluated by MarketBeat, and ranked 830th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arbutus Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for Arbutus Biopharma is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Arbutus Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Arbutus Biopharma is 5.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.03.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arbutus Biopharma is 5.80, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 210.49.

Price to Book Value per Share Ratio

Arbutus Biopharma has a P/B Ratio of 11.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.79% of the float of Arbutus Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Arbutus Biopharma has a short interest ratio ("days to cover") of 13.69, which indicates bearish sentiment.

Change versus previous month

Short interest in Arbutus Biopharma has recently increased by 2.97%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arbutus Biopharma does not currently pay a dividend.

Dividend Growth

Arbutus Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: -0.01

News Sentiment

Arbutus Biopharma has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.

Search Interest

10 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.

MarketBeat Follows

2 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.90% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ABUS
• CIK: 1447028
• Web: www.arbutusbio.com
• Phone: (267) 469-0914
• Fax: 604-419-3201
• Employees: 90
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Arbutus Biopharma: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +9.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.83
• Trailing P/E Ratio: 5.80
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.50 million
• Net Margins: 84.22%
• Pretax Margin: 83.95%
• Return on Equity: 110.87%
• Return on Assets: 97.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 54.26
• Quick Ratio: 54.26

Sales & Book Value

• Annual Sales: $14.08 million
• Price / Sales: 64.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 11.45

Miscellaneous

• Outstanding Shares: 197,540,000
• Free Float: 158,228,000
• Market Cap: $904.73 million
• Optionable: Optionable
• Beta: 0.64